These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34632560)

  • 1. Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers.
    Nanami T; Hoshino I; Shiratori F; Yajima S; Oshima Y; Suzuki T; Ito M; Hiwasa T; Kuwajima A; Shimada H
    Int J Clin Oncol; 2022 Jan; 27(1):72-76. PubMed ID: 34632560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of autoantibodies against Ras-like GTPases, RalA, in patients with gastric cancer.
    Nanami T; Hoshino I; Ito M; Yajima S; Oshima Y; Suzuki T; Shiratori F; Nabeya Y; Funahashi K; Shimada H
    Mol Clin Oncol; 2020 Oct; 13(4):28. PubMed ID: 32765875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
    Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
    J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible predictive significance of serum RalA autoantibodies on relapse-free survival in patients with colorectal cancer.
    Ushigome M; Shimada H; Nabeya Y; Shiratori F; Soda H; Takiguchi N; Hoshino I; Kuwajima A; Kaneko T; Funahashi K
    Mol Clin Oncol; 2021 Jan; 14(1):18. PubMed ID: 33363728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-panel assay of serum autoantibodies in colorectal cancer.
    Ushigome M; Nabeya Y; Soda H; Takiguchi N; Kuwajima A; Tagawa M; Matsushita K; Koike J; Funahashi K; Shimada H
    Int J Clin Oncol; 2018 Oct; 23(5):917-923. PubMed ID: 29691673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study.
    Okada R; Otsuka Y; Yokosuka O; Kato N; Imazaki F; Hoshino I; Sugiura N; Mizumoto H; Azemoto R; Kato K; Shimada H
    Oncol Lett; 2022 Oct; 24(4):367. PubMed ID: 36238856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
    Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
    Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers.
    Hoshino I; Nabeya Y; Takiguchi N; Gunji H; Ishige F; Iwatate Y; Shiratori F; Yajima S; Okada R; Shimada H
    Ann Gastroenterol Surg; 2020 May; 4(3):275-282. PubMed ID: 32490341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery.
    Oshima Y; Suzuki T; Yajima S; Nanami T; Shiratori F; Funahashi K; Shimada H
    Surg Today; 2020 Nov; 50(11):1402-1408. PubMed ID: 32458231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.
    Shimada H; Shiratori T; Takeda A; Matsushita K; Okazumi S; Akutsu Y; Matsubara H; Nomura F; Ochiai T
    World J Surg; 2009 Feb; 33(2):272-7. PubMed ID: 19052812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
    Dong J; Zeng BH; Xu LH; Wang JY; Li MZ; Zeng MS; Liu WL
    J Transl Med; 2010 Sep; 8():81. PubMed ID: 20813067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of autoantibodies against p53 in Taiwanese lung cancer patients undergoing chemotherapy.
    Lee YL; Shih CM; Chiou HL; Shiau MY; Chang GC; Chang YH
    Clin Chim Acta; 2004 Nov; 349(1-2):87-96. PubMed ID: 15469860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma.
    Cai HY; Wang XH; Tian Y; Gao LY; Zhang LJ; Zhang ZY
    World J Gastroenterol; 2008 Jul; 14(25):4082-6. PubMed ID: 18609695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
    Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
    Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.
    Shimizu K; Ueda Y; Yamagishi H
    Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
    Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
    Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Assay System Elecsys Anti-p53 to Detect Serum Anti-p53 Antibodies in Esophageal Cancer Patients and Colorectal Cancer Patients: Multi-institutional Study.
    Yajima S; Suzuki T; Oshima Y; Shiratori F; Funahashi K; Kawai S; Nanki T; Muraoka S; Urita Y; Saida Y; Okazumi S; Kitagawa Y; Hirata Y; Hasegawa H; Okabayashi K; Murakami M; Yamashita T; Kato R; Matsubara H; Murakami K; Nakajima Y; Sugita H; Klammer M; Shimada H
    Ann Surg Oncol; 2021 Jul; 28(7):4007-4015. PubMed ID: 33210269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases.
    Neri M; Betta P; Marroni P; Filiberti R; Cafferata M; Mereu C; Ivaldi G; Montanaro F; Puntoni R; Paganuzzi M
    Lung Cancer; 2003 Feb; 39(2):165-72. PubMed ID: 12581569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy.
    Blanchard P; Quero L; Pacault V; Schlageter MH; Baruch-Hennequin V; Hennequin C
    BMC Cancer; 2012 Mar; 12():119. PubMed ID: 22448886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.